Cardiovascular Innovation & Research Institute 's NEXUS Registry, the Whole is Greater Than the Parts.
NCT ID: NCT03428048
Last Updated: 2020-06-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1000 participants
OBSERVATIONAL
2016-03-31
2030-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Feasibility, Safety, and Effectiveness of the ACURATE neo2 Transcatheter Heart Valve for Severe Bicuspid Aortic Stenosis
NCT06212050
Structural Heart and Valve Network PROSPECTIVE Registry
NCT03928639
Valvular Heart Disease Registry
NCT03488732
Early neo2 Registry of the Acurate neo2 TAVI Prosthesis
NCT04810195
Hybrid Revascularization Observational Study
NCT01121263
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The ADVARRA formerly Schulman Institutional Review Board (IRB) reviewed our protocol, and authorized the study. Once informed consent was obtained, eligible adults scheduled for diagnostic angiography with possible PCI completed a baseline patient reported outcome assessment and again at designated follow-up intervals (six months and annually thereafter for up to ten years). Due to the urgent nature of STEMI- PCI procedures, it was determined that informed consent prior to PCI was prohibitive; however after consideration, the protocol was amended to capture baseline assessments immediately following PCI while the patient 's status was in hospital with use of the Seattle Angina Questionnaire (SAQ) and the Veterans Rand 12-Item Health Survey (VR-12). The SAQ is recognized as a disease specific questionnaire for coronary artery disease. The SAQ is a six item questionnaire that assesses patient's function, symptoms, and satisfaction. A higher score translates to better outcomes. The VR-12 is a twelve item questionnaire used to assess quality of life. A lower score translates to a higher quality of life in relation to a person's health and wellness. Combining data from a disease specific questionnaire, quality of life assessment, and the NCDR's CathPCI® Registry serves as a nexus between big data and the individual patient experience. From January 2015 through December 2017, twenty- two patients have been enrolled. Based on the data from the first six patients to provide scores both at baseline and month six and with a study design to have 90% power to detect a change in the overall SAQ score of 10 points at six months, it was determined 49 patients will need to be enrolled.
The aforementioned methodology will be applied for surgical and endocardial ablations for patients' with Afib. Presently, enrollment is open for Afib patients and data being captured will be analyzed to determine sample size. Patients who receive intervention for management Afib will complete the Atrial Fibrillation Effect on Quality -of-life (AFEQT) Questionnaire and the VR-12. Again the VR-12 is a twelve item questionnaire used to assess quality of life. A lower score translates to a higher quality of life in relation to a person's health and wellness. The AFEQT is recognized as a disease specific questionnaire for Afib. A higher score translates to worse symptoms and limitations in daily function associated with Afib. Combining the outcomes metric with NCDR's Afib Ablation Registry ® allows our institution demonstrative effective outcomes for low-volume operators.
The data validation process applies to both PCI and surgical and/or endocardial ablation and is as follows:
1. Quality Assurance Plan Training for staff that populates both data registries is ongoing. Staff will participate in the NCDR® applicable training modules. Documentation of training will be maintained in the study coordinator's office. Agreeing to participate with the NCDR®, an institution also agrees to random site monitoring and/or audits.
2. Data Checks All patients who agree to participate in NEXUS outcomes registry and subsequent statistical analysis will experience a complete date audit for both outcomes assessments and NCDR® data elements. NCDR® has algorithm limits for both CathPCI® Registry and Afib Ablation ® Registry. All registry elements require abstraction form Meditech source documents. Reports are titled Cardiology Procedure Note and Electrophysiology Procedure Note for PCI and Afib ablation, respectively. Quality/outcome metrics will be sampled in paper form -the sources documents. Information will then be populated into excel for scoring. All paper forms will be maintained for the life of the study.
3. Data Dictionary Complete Data Dictionaries are provided by NCDR® with data element numbers and associated limits and acceptable values for both Cath PCI ® and Afib Ablation ® Registry.
4. Standard Operating Procedures A complete NEXUS Registry Protocol will be on site held in the Cardiovascular Innovation \& Research Institute at Valley View Hospital along with all regulatory information, lab certifications, training documents, IRB documents, license agreements, analytic agreements and process maps for informed consent for outcomes research. Note NCDR® registries obtained a waiver for informed consent.
5. Sample Size Assessment The number of patients necessary to demonstrate an effect for outcomes after PCI with low-volume operators is 49.
Presently, outcomes after surgical and/or endocardial ablation are being piloted to determine sample size for a study powered at 90%.
6. Missing Data Every attempt will be made to reach patients to ensure they are not lost to follow-up. Statistical consult recommends last observation carried forward for missing data.
7. Statistical Analysis Plan. For the primary analysis, the 6-month change in mean SAQ will be tested using a 1-sample upper 1-sided t-test. With 49 completers the t-test will have 90.4% power to detect an improvement in mean SAQ score of 10 points. A linear regression model will be used for the secondary analysis to investigate factors which are associated with the 6-month change (month 6 - baseline) in mean SAQ score. Factors which will be investigated for inclusion in the model include sex, age, physician American Society Anesthesiologists (ASA) class, physician volume, access site, and Charlson comorbidity index. An all-possible regressions approach will be used during the model building process in which all possible regression models are fit. The models will then be evaluated using Mallows' Cp statistic where models with values of Cp less than p (the number of parameters) will be considered as strong candidates for the final model. The final model will be selected after considering both results from the model selection process and subject matter knowledge. The regression analysis will have greater power than the t-test used in the sample size justification due to the reduction in variability of the outcome measure by including additional factors in a regression model. Additional analyses include \[need to add specifics here\]. All analyses will be conducted using SAS 9.4M4 or greater software (SAS Institute, Inc., Cary, NC, USA).
Morbidity / Complications will be reported included but not limited to bleeding at access site, hematoma, cardiac tamponade, vascular perforation, peripheral vascular injuries, post procedure hematoma, and mortality.
Statistical Analysis Plan with Respect to Surgical and/ or Endocardial Ablation for Afib
This outcomes registry is in its early pilot analysis for Afib and hypothesis generating. For the primary analysis, the six-month change in mean AFEQT scores will be analyzed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Adults diagnosed with paroxysmal and persistent Afib
Adults diagnosed with paroxysmal and persistent Afib who are identified as candidates for an intervention either surgical (epicardial) known as the hybrid approach or an endocardial ablation with either laser, radio frequency or cryoablation energy source.
Hybrid procedure
Ablation of the posterior aspect of the heart, an area thought to be the origin of chaotic arrhythmias in persistent Afib patients.
Endocardial ablations
ablations occurring inside the heart isolating the pulmonary veins - blocking energy from creating irregular or chaotic heart beats with use of a catheter
left atrial appendage occlusion
A procedure to isolate the left atrial appendage of the heart. this anatomic body is the origin of clot formation which can lead to stroke. the clot formation as a result of Afib
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hybrid procedure
Ablation of the posterior aspect of the heart, an area thought to be the origin of chaotic arrhythmias in persistent Afib patients.
Endocardial ablations
ablations occurring inside the heart isolating the pulmonary veins - blocking energy from creating irregular or chaotic heart beats with use of a catheter
left atrial appendage occlusion
A procedure to isolate the left atrial appendage of the heart. this anatomic body is the origin of clot formation which can lead to stroke. the clot formation as a result of Afib
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Age \>18 years
2. The subject has been informed of the nature of the study, agrees to its provisions, is able to comprehend, and has provided informed consent.
3. The subject is available for follow-up.
4. The subject has a diagnosis of coronary artery disease or Afib.
Exclusion Criteria
1. Failure and / or inability and / or unwillingness to provide informed consent.
2. Likely problems, in the judgement of the investigators, with maintaining follow-up.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Valley View Hospital
UNKNOWN
Cardiovascular Innovation and Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Frank A Laws, MD
Role: PRINCIPAL_INVESTIGATOR
Valley View Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Valley View Hospital
Glenwood Springs, Colorado, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015_01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.